Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.06
-0.3600-3.82%
Post-market: 9.05-0.0100-0.11%19:59 EDT
Volume:3.26M
Turnover:29.57M
Market Cap:526.74M
PE:-3.67
High:9.36
Open:9.30
Low:8.96
Close:9.42
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:45.54M
Volume Ratio:1.21
T/O Rate:7.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.14
PE(LYR):-4.01

Loading ...

Capricor Says Deramiocel Meets Primary Endpoint in Hope-3 Phase 3 Duchenne Muscular Dystrophy Trial

Reuters
·
Jun 26

Capricor Therapeutics EVP, General Counsel Karen Krasney Sells 900 Shares for $27,000

Reuters
·
Jun 25

Analysts Offer Insights on Healthcare Companies: Odyssey Therapeutics, Inc. (ODTX), Capricor Therapeutics (CAPR) and Medtronic (MDT)

TIPRANKS
·
Jun 18

Capricor Therapeutics shareholders reject officer exculpation charter amendment at annual meeting

Reuters
·
Jun 09

Capricor Therapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
Jun 08

Why Capricor Therapeutics (CAPR) Is Down 10.8% After FDA Clears Key Deramiocel Inspection Step

Simply Wall St.
·
Jun 07

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 29

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

Capricor Therapeutics files Form 3 for Chief Commercial Officer Michael T. Maurer

Reuters
·
May 29

A Look At Capricor Therapeutics (CAPR) Valuation After Deramiocel Launch Delay And Milestone Cut

Simply Wall St.
·
May 25

Capricor publishes investor presentation on deramiocel Duchenne muscular dystrophy program

Reuters
·
May 21

Capricor Faces Revenue Risk as Dependence on Nippon Shinyaku Puts Deramiocel Commercialization in Jeopardy

TIPRANKS
·
May 15

Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 15

Assessing Capricor Therapeutics (CAPR) Valuation After Strong Multi Year Gains And Recent Share Price Pullback

Simply Wall St.
·
May 14

Capricor Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.

Dow Jones
·
May 13

BRIEF-Capricor Therapeutics Reports First Quarter 2026 Financial Results

Reuters
·
May 13

Capricor Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Capricor Therapeutics Q1 Loss Widens

MT Newswires Live
·
May 13

Capricor Q1 FY26 net loss widens to $33.9 million; revenue remains no revenue

Reuters
·
May 13

Capricor Therapeutics options imply 9.4% move in share price post-earnings

TIPRANKS
·
May 13